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Key questions
What is already known?
 ► As Zika virus (ZIKV) has been most prevalent in 
subtropical and tropical regions with high burdens 
of cocirculating infectious agents, a proportion of 
ZIKV infections occur simultaneously with infections 
by one or multiple other pathogens; however, it is 
uncertain whether coinfections may influence ZIKV- 
related pathology.
What are the new findings?
 ► This systematic review collated the evidence on ZIKV 
coinfections as published in 34 studies in 10 coun-
tries. ZIKV coinfections were most frequently report-
ed in the context of the arthropod- borne viruses, 
dengue and chikungunya, but were also described 
in relation to eight other pathogens.
 ► While the findings of this review suggest that coin-
fections do not appear to strongly influence the clini-
cal manifestations of uncomplicated ZIKV infections, 
this review did identify reports of neurological com-
plications in the context of coinfection.
What do the new findings imply?
 ► The findings of this review highlight a need for co-
ordinated and rapid research efforts during future 
outbreaks to optimise diagnostic testing strategies 
for detecting coinfections and determining whether 
they may exacerbate the risk of severe ZIKV compli-
cations, such as Guillain- Barré syndrome and con-
genital Zika syndrome.
ABSTRACT
Background There is limited knowledge on the influence 
of concurrent coinfections on the clinical presentation of 
Zika virus (ZIKV) disease.
Methods To better understand the types, frequencies 
and clinical manifestations of ZIKV coinfections, we did a 
systematic review of four databases (PubMed, Embase, 
Web of Science, LILACS) without restrictions for studies on 
ZIKV coinfections confirmed by nucleic acid (quantitative 
real- time- PCR) testing of ZIKV and coinfecting pathogens. 
The review aimed to identify cohort, cross- sectional, case 
series and case report studies that described frequencies 
and/or clinical signs and symptoms of ZIKV coinfections. 
Conference abstracts, reviews, commentaries and studies 
with imprecise pathogen diagnoses and/or no clinical 
evaluations were excluded.
Results The search identified 34 articles from 10 
countries, comprising 2 cohort, 10 cross- sectional, 8 
case series and 14 case report studies. Coinfections were 
most frequently reported to have occurred with other 
arthropod- borne viruses (arboviruses); out of the 213 
coinfections described, ZIKV infections co- occurred with 
chikungunya in 115 cases, with dengue in 68 cases and 
with both viruses in 19 cases. Other coinfecting agents 
included human immunodeficiency, Epstein- Barr, human 
herpes and Mayaro viruses, Leptospira spp, Toxoplasma 
gondii and Schistosoma mansoni. ZIKV- coinfected cases 
primarily presented with mild clinical features, typical 
of ZIKV monoinfection; however, 9% of cases in cohort 
and cross- sectional studies were reported to experience 
complications.
Conclusion Based on the evidence collated in this review, 
coinfections do not appear to strongly influence the clinical 
manifestations of uncomplicated ZIKV infections. Further 
research is needed to confirm whether risk of severe 
complications is altered when ZIKV infection co- occurs 
with other infections.
PROSPERO registration number CRD42018111023.
InTROduCTIOn
Zika virus (ZIKV) is an Aedes mosquito- borne 
flavivirus that recently emerged in the Amer-
icas.1 First recognised in Brazil in early 2015, 
the ZIKV epidemic spread explosively, with 
autochthonous transmission reported in 
more than 86 countries and territories by 
2018.1 Given the widespread circulation of this 
emerging infection of public health concern, 
it is critical that healthcare practitioners can 
readily recognise ZIKV disease across the full 
range of its clinical presentations.
Current evidence indicates that ZIKV infec-
tions typically present with no or mild clinical 
features.1 A 2018 meta- analysis of 23 studies 
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by Haby and colleagues estimated a prevalence of asymp-
tomatic ZIKV infections of 62% (95% CI 33% to 87%).2 
For symptomatic ZIKV disease, the WHO describes a mild 
clinical presentation marked by fever, rash, conjunctivitis, 
myalgia, arthralgia, malaise and headache.1 Nevertheless, 
ZIKV is neurotropic and, in a subset of cases, infections 
have been associated with severe neurological compli-
cations, including the polyneuropathy Guillain- Barré 
syndrome (GBS) and congenital Zika syndrome (CZS), a 
constellation of congenital central nervous system malfor-
mations resulting from the vertical transmission of ZIKV 
during pregnancy.3 It has been estimated that GBS arises 
in approximately 2 per 10 000 ZIKV infections,1 4 and the 
absolute risk of adverse birth outcomes (ie, miscarriage, 
stillbirth, premature birth and CZS) has been reported 
to range between 7% and 46% in pregnancies with 
quantitative real- time PCR (qRT- PCR)- confirmed ZIKV 
infection.5–8
Although the clinical presentation of ZIKV monoin-
fections has been well characterised, one factor that may 
influence the clinical spectrum of ZIKV disease is coin-
fection. Given the high incidence of infectious diseases 
in the subtropical and tropical areas where ZIKV is prev-
alent, a proportion of all ZIKV infections occur concur-
rently with infections by one or multiple pathogens.9 
ZIKV disease in the context of coinfection remains inad-
equately investigated, and it is uncertain whether specific 
coinfections may influence the presentation and severity 
of ZIKV- related signs and symptoms. A 2019 literature 
review by Vogels and colleagues hypothesised that coin-
fecting agents have the potential to enhance, inhibit, 
compete with or have no effect on ZIKV replication 
and the resulting clinical disease.10 To advance under-
standing on this topic, this systematic review aims to 
quantify how frequently ZIKV coinfections occur among 
ZIKV- infected populations and to investigate whether the 
clinical course of ZIKV disease in humans is altered in the 
context of coinfection.
METHOdS
Search
Four databases (PubMed, Web of Science, LILACs and 
EMBASE) were searched for publications up to 19 
October 2019 using a comprehensive search strategy 
(online supplementary appendix 1). Keywords and 
Medical Subject Headings linked to ZIKV, bacterial, 
parasitic and other viral infectious diseases were used. 
The search included English, French, Spanish and 
Portuguese terms. No date or language restrictions were 
applied. The systematic review was registered in PROS-
PERO. All study titles and abstracts were screened based 
on eligibility criteria, and references of included studies 
were also screened to identify additional eligible articles.
Study selection and data extraction
Cohort studies, cross- sectional studies, case series and 
case reports describing coinfections of ZIKV with one 
or multiple other pathogens, confirmed by nucleic acid 
testing (eg, qRT- PCR) for ZIKV, and all coinfecting path-
ogens were eligible for inclusion in the review. Recovery 
of live pathogens was also considered to be indicative of 
acute coinfection. Of note, HIV- positive ZIKV cases with 
HIV suppression were not included in this review. Two 
reviewers (AR and LL) simultaneously screened studies 
for eligibility, and any discrepancies were resolved by a 
third reviewer (EBB). Conference abstracts, reviews, 
commentaries and studies without nucleic acid confir-
mation were excluded. Whereas cohort, cross- sectional 
and case series studies reporting on numbers of ZIKV 
coinfections without description of signs and symptoms 
were included to describe the frequency of ZIKV coin-
fections, studies with no reporting of signs and symptoms 
of ZIKV coinfections were otherwise excluded from the 
review. Data extraction was independently performed 
by two reviewers (AR, LL). From the full- text articles, 
information on study author, location, year, data source, 
age and sex of identified cases was extracted. Additional 
extracted information included frequencies of ZIKV 
cases with coinfection, types of coinfection, types of 
diagnostic testing, reported signs and symptoms, non- 
infectious comorbidities, and types and frequencies of 
complications. To investigate the frequency of ZIKV coin-
fections in cohort, cross- sectional and case series studies, 
the numbers of coinfections out of the total number 
of qRT- PCR- confirmed ZIKV cases were calculated for 
the eligible studies. The study quality assessment was 
conducted using the Oxford Centre for Evidence- based 
Medicine (OCEBM) Levels of Evidence, March 200911; 
see online supplementary appendix 2 for details.
Patient and public involvement
This research was done without patient or public involve-
ment.
RESulTS
Study selection
The search initially identified 12 253 titles, of which 
12 050 titles were excluded after screening titles and 
abstracts and removing duplicates (figure 1). Full- text 
screening was completed for 203 publications, and, ulti-
mately, 34 articles representing coinfections in 10 coun-
tries were included (tables 1–4 and figure 2).
ZIKV coinfection types
ZIKV infections were most frequently reported to occur 
concurrently with other arthropod- borne viruses (arbo-
viruses). Out of the 213 coinfections examined, there 
were 115 ZIKV/chikungunya virus (CHIKV) coinfection 
cases, 68 ZIKV/dengue virus (DENV) coinfection cases 
and 19 cases coinfected with all three viruses. Other 
reported ZIKV coinfections included ZIKV/HIV (n=3), 
ZIKV/Leptospira spp (n=2), ZIKV/CHIKV/HIV/Toxo-
plasma gondii (n=1), ZIKV/CHIKV/Toxoplasma gondii 
(n=1), ZIKV/Epstein- Barr virus (EBV)/human herpes 
viruses-6 (HHV-6) (n=1), ZIKV/herpes simplex virus-1 
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Figure 1 Study selection.
*Studies reporting on both clinical signs and symptoms and 
frequency of Zika virus coinfections (n=27); studies reporting 
only on Zika virus coinfection frequencies (n=7).
qRT- PCR, quantitative real- time PCR; ZIKV, Zika virus.
(HSV-1) (n=1), ZIKV/Mayaro virus (MAYV) (n=1) and 
ZIKV/Schistosoma mansoni (n=1) (figure 3).
Frequencies of ZIKV coinfections
The frequencies of coinfections among ZIKV- infected 
populations were reported in 11 studies, including 1 
cohort study, 7 cross- sectional studies and 3 case series 
(table 1, online supplementary table 2). Frequency esti-
mates were reported only for coinfections with CHIKV and 
DENV and varied geographically and across study popu-
lations at risk. Among patients presenting with arbovirus- 
like symptoms, ZIKV/CHIKV coinfection frequencies 
were reported to range from 0.3% in a study in Colombia 
to 54% in a study in Brazil.5 9 12–14 Similarly, ZIKV/DENV 
coinfection frequencies in patients with arbovirus- like 
symptoms were reported to range from 0.03% in a study 
in Colombia to 47.4% in a study in Brazil.9 13 15–19 ZIKV/
CHIKV/DENV coinfection frequencies ranged from 8% 
in a study in Nicaragua to 27.6% in a study in Colombia.9 13
Signs and symptoms of coinfections
In total, 27 studies, including 1 cohort study, 5 cross- 
sectional studies, 7 case series and 14 case report studies, 
reported the signs and symptoms of ZIKV coinfection 
across a total of 106 ZIKV- coinfected cases.
ZIKV/CHIKV coinfections
The clinical presentations of 48 cases with ZIKV/CHIKV 
coinfection were reported in 1 cohort study, 1 cross- 
sectional study, 4 case series and 6 case reports (tables 2–4, 
online supplementary tables 1 and 2).20–28 Within the 
cohort, cross- sectional and case series studies, cases were 
reported to present with the following signs and symp-
toms consistent with the WHO ZIKV clinical case defini-
tion1: fever (33%–100%), rash (0%–100%), conjunctivitis 
(0%–50%), myalgia (67%–100%), arthralgia (0%–67%) 
and headache (17%–50%) (tables 2 and 3). In addition, 
gastrointestinal (GI) symptoms were reported in 17% to 
100% of cases in three studies (tables 2 and 3).20 21 23
Complications were reported among 14.7% (5 cases) 
of ZIKV/CHIKV- coinfected cases in cohort and cross- 
sectional studies,22–27 of whom two adult cases presented 
with unspecified neurological complications that resulted 
in death (figure 4).28 Additionally, two coinfections in 
pregnancy were associated respectively with anencephaly 
and an absence of a heartbeat.28 A non- neurological 
complication reported was a case that died from multi-
organ failure following haemorrhagic manifestations.23 28 
The case series studies described that six out of eight 
ZIKV/CHIKV- coinfected cases developed complications, 
which included neurological manifestations, such as GBS 
in two cases,22 29 encephalitis in one case,22 myeloradicu-
litis in one case,29 as well as non- neurological complica-
tions, such as persistent severe arthralgia in one case.23 
Additionally, four case reports described ZIKV/CHIKV 
coinfection- associated complications, including GBS in 
two cases,24 27 persistent severe arthralgia in one case26 
and sepsis resulting in death in one case.25
ZIKV/dEnV coinfections
The clinical features of 42 cases with ZIKV/DENV 
coinfection were described across four cross- sectional 
studies, three case series and five case reports (tables 2–4, 
online supplementary tables 1 and 2).15 18 19 30–33 Cases 
with ZIKV/DENV coinfection within the cross- sectional 
and case series studies were reported to present with 
the following signs and symptoms consistent with the 
WHO ZIKV clinical case definition1: fever (58%–100%), 
rash (53%–100%), conjunctivitis (25%–100%), myalgia 
(75%–100%), arthralgia (50%–100%) and headache 
(50%–100%) (tables 2 and 3). Other reported clinical 
features included GI symptoms in 17%–75% of cases and 
upper respiratory tract (URT) symptoms in 13%–25% of 
cases (tables 2 and 3).
Complications were reported among none of the 
ZIKV/DENV- coinfected individuals in cohort and 
cross- sectional studies (figure 4). However, seven cases 
with complications were reported in case series, which 
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Figure 2 Studies included in the systematic review: cohort studies (n=2), cross- sectional studies (n=10), case series 
studies (n=8) and case reports (n=21 reported in 14 case report studies). Two cohort studies on ZIKV/CHIKV coinfections 
were conducted in Haiti (n=1) and Brazil (n=1). Ten cross- sectional studies were conducted in Brazil (n=6), Colombia (n=2), 
Nicaragua (n=1) and Peru (n=1). Eight case series were reported from Brazil (n=5), Ecuador (n=1) and Singapore (n=2). Twenty- 
one case reports were reported from Brazil (n=6), Colombia (n=6), Ecuador (n=3), Mexico (n=1), New Caledonia (n=3), Puerto 
Rico (n=1) and the USA (n=1). CHIKV, chikungunya virus; DENV, dengue virus; EBV, Epstein- Barr virus; HSV, herpes simplex 
virus; MAYV, Mayaro virus; ZIKV, Zika virus.
Figure 3 Zika virus coinfection types identified in this 
systematic review. Size of circles represents the number of 
cases reported per coinfection type. In total, 213 coinfection 
cases were included, ie, ZIKV/CHIKV (n=115), ZIKV/
DENV (n=68), ZIKV/CHIKV/DENV (n=19), ZIKV/HIV (n=3), 
ZIKV/Leptospira spp (n=2), ZIKV/HIV/Toxoplasma gondii 
(n=1), ZIKV/CHIKV/Toxoplasma gondii (n=1), ZIKV/HSV-1 
(n=1), ZIKV/Schistosoma mansoni (n=1), ZIKV/EBV/HHV-6 
(n=1), ZIKV/MAYV (n=1. CHIKV, chikungunya virus; DENV, 
dengue virus; EBV, Epstein- Barr virus; HHV, human herpes 
virus; HSV, herpes simplex virus; MAYV, Mayaro virus; ZIKV, 
Zika virus.
presented respectively with painful hepatomegaly, liver 
enlargement, mucosal bleeding, gingival bleeding, 
significant thrombocytopenia and abrupt platelet 
decrease.15 18 19 The only neurological complications 
resulting from ZIKV/DENV coinfection were reported in 
two case reports documenting infections in pregnancy, 
with one case resulting in a newborn with functional 
plagiocephaly and the other in fetal death (table 3).19
ZIKV/CHIKV/dEnV coinfections
The clinical presentation of five cases with ZIKV/
CHIKV/DENV coinfection were described in one case 
series (four cases) and one case report (tables 3 and 
4, online supplementary tables 1 and 2).22 34 Similar to 
ZIKV/CHIKV and ZIKV/DENV- coinfected cases, ZIKV/
CHIKV/DENV- coinfected cases presented with signs and 
symptoms consistent with the ZIKV WHO clinical case 
definition.1 All five cases were reported to have compli-
cations (figure 4). The case series reported GBS in two 
cases, one case of meningitis and one case of encephalitis, 
which resulted in death. Notably, the study’s population 
was selected to include only clinical patients presenting 
to hospital with neurological symptoms.22 The case report 
documented one case of cervical lymphadenopathy in 
pregnancy and full recovery.35
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Figure 4 Complications resulting from Zika virus coinfections with CHIKV and DENV by study design. In cohort and cross- 
sectional studies, 15% of ZIKV/CHIKV coinfections resulted in complications. In case series, 41% of ZIKV/DENV, 75% of ZIKV/
CHIKV and 100% of ZIKV/CHIKV/DENV cases resulted in in complications. In case reports, two ZIKV/DENV, two ZIKV/CHIKV 
and one ZIKV/CHIKV/DENV coinfections resulted in complications. CHIKV, chikungunya virus; CZS, congenital Zika syndrome; 
DENV, dengue virus; GBS, Guillain- Barré syndrome; n, number of complications; ZIKV, Zika virus.
Other ZIKV coinfections
There is limited published evidence on ZIKV coinfec-
tions with other pathogens. To date, the clinical signs and 
symptoms of 10 cases with eight other ZIKV coinfection 
types have been documented in one cross- sectional study, 
one case series and seven case reports (tables 2–4, online 
supplementary tables 1 and 2).34 36–42
In addition to presenting with signs and symptoms 
consistent with the WHO ZIKV clinical case definition, 
almost all cases of ZIKV coinfections with pathogens 
other than DENV or CHIKV were reported to experi-
ence complications. Neurological complications were 
reported in two ZIKV/HIV coinfections, one ZIKV/
CHIKV/HIV/Toxoplasma gondii coinfection and one 
ZIKV/HSV-1 coinfection. These neurological compli-
cations included meningitis, meningoencephalitis and 
demyelinations confirmed by electromyography.22 34 38 
Further, one ZIKV/HIV- coinfected case developed sepsis, 
resulting in death.34 Two ZIKV/Leptospira spp- coinfected 
cases developed haemodynamic instability, one resulting 
in septic shock,and one in death.39 40 Additionally, one 
ZIKV/Schistosma mansoni- coinfected case experienced 
testicular inflammation with granulomas induced by 
schistosome eggs.41
Coinfections in pregnancy were described in three 
ZIKV coinfection types: ZIKV/MAYV, ZIKV/CHIKV/
Toxoplasma gondii and ZIKV/EBV/HHV6 coinfec-
tions.36 37 42 In the latter two, vertical ZIKV transmission 
was suspected, as both fetuses were diagnosed with CZS. 
After diagnosis, one pregnancy was terminated at 29 
weeks of gestation and one newborn died 4 hours after 
birth at 30 weeks of gestation due to respiratory distress 
syndrome.
levels of evidence
The levels of evidence for the studies were assessed using 
the OCEBM Levels of Evidence (1=highest, 5=lowest). 
Two cohort studies with limited follow- up were graded 
evidence level 2b.5 20 Ten cross- sectional studies were 
graded evidence level 2c.9 12–14 17 19 28 30 42 43 Eight case 
series studies were graded evidence level 4.15 16 18 21–23 29 31 
Fourteen case report studies were graded evidence level 
5.19 24–27 32–41 Thus, most of the studies included in the 
systematic review are evidence level 4 or 5.
dISCuSSIOn
This systematic review summarises the existing literature 
on ZIKV coinfections. Specifically, it describes the esti-
mated frequencies of reported ZIKV coinfections and 
their clinical spectrum. The search identified 34 studies 
conducted between 2014 and 2019, which reported 213 
cases of ZIKV coinfection with 10 different pathogens. 
ZIKV coinfections were detected across 10 countries, 
primarily in Latin America. CHIKV and DENV were the 
predominantly reported ZIKV coinfecting agents and the 
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only ZIKV coinfections for which population frequencies 
were described. ZIKV coinfection frequencies among 
ZIKV- infected cases varied significantly between location 
and population type. The vast majority of ZIKV- coinfected 
cases were reported to present with the signs and symp-
toms described for uncomplicated ZIKV monoinfections 
and defined by the WHO.1 However, complications were 
reported to arise in 9% of ZIKV- coinfected cases in cohort 
and cross- sectional studies.
This is the first systematic review to study how 
frequently individuals with ZIKV infection have a coex-
isting infection of any kind. The variation in frequen-
cies reported for ZIKV/arbovirus coinfections among 
the ZIKV- infected individuals reported in this study was 
likely influenced by differences in study design and the 
selected study population. Factors, such as study loca-
tion, season and study period in relation to the ZIKV 
outbreak, will have additionally influenced ZIKV coin-
fection frequency estimates. As expected, ZIKV coinfec-
tions were relatively more common in studies conducted 
during concurrent arbovirus outbreaks.14 44 These differ-
ences in study design, timing and location make it diffi-
cult to generalise ZIKV coinfection frequency estimates, 
but provide important knowledge that arbovirus coin-
fections can occur in up to half of ZIKV- infected cases 
in certain contexts. Our findings are consistent with a 
systematic review of CHIKV/DENV coinfections, which 
found the frequency of CHIKV/DENV coinfections 
reported in 28 studies ranged from 1% to 36%.45 The 
heterogeneity across studies also reflects the difficulty in 
estimating the background level of ZIKV infections (ie, 
the denominator for assessing coinfection frequencies), 
given the diagnostic challenges in identifying acute ZIKV 
infections.46
Overall, the evidence identified in this review suggests 
that ZIKV coinfections appear to present with a mild 
clinical presentation similar to that previously described 
for ZIKV monoinfections. Of note, GI and URT symp-
toms, which are considered uncharacteristic for ZIKV, 
were reported to occur not infrequently in ZIKV/DENV, 
ZIKV/CHIKV and ZIKV/CHIKV/DENV- coinfected 
cases. While the evidence base from animal model 
studies of ZIKV coinfection is limited to date, two studies 
have compared ZIKV infection among rhesus macaque 
models with and without simian immunodeficiency 
virus or chimeric simian HIV.47 48 Whereas coinfected 
macaques were observed to have lower peak Zika viral 
loads with a longer clearance time in both investigations, 
the area under the viral load curves did not appear to 
differ substantively by coinfection status, potentially 
suggesting an overall limited impact of coinfection on 
disease progression but raising questions about the role 
of lentiviral coinfection in onward transmission.47 48
Although the existing reports suggest that coinfections 
do not appear to markedly alter the clinical presenta-
tion of uncomplicated ZIKV disease in humans, the 
findings from this review highlight a need for additional 
high quality research investigating whether coinfections 
may influence complication risks. Based on the limited 
available evidence, the complications described for 
ZIKV coinfections appear to be broadly similar to those 
reported for ZIKV monoinfections.49 However, 33% of 
the coinfection- related complications appeared to be 
atypical for ZIKV monoinfections, but were consistent 
with complications previously documented for the coin-
fecting pathogens (eg, bleeding in 10% of ZIKV/DENV 
cases and persistent arthralgia in 6% of ZIKV/CHIKV 
cases).50 51 In addition, among deaths of ZIKV- coinfected 
cases, three of the nine cases had immune deficiencies 
and one ZIKV/Leptospira spp- coinfected case died from 
complications established for Leptospira spp infections.40 
The remaining five deaths reported from ZIKV coinfec-
tions were three fetal deaths, one case following multi-
organ failure and one case following encephalitis.22 28 
Additionally, some complications may have been missed, 
especially those that occurred after the acute infections, 
as the follow- up period of the individual studies may have 
not been adequate to detect late- onset complications. 
Further research (eg, an ongoing cohort study of ZIKV/
HIV coinfections in pregnant women52) will be valuable 
for discerning the relative risk of complications of ZIKV 
coinfection versus monoinfections.
This review had strengths and limitations. ZIKV is an 
emerging infectious disease of significant public health 
concern, and this is the first systematic review of the 
frequency, types and clinical presentation of ZIKV coin-
fections. The study employed a broad search strategy 
including search terms for all potential coinfecting 
pathogens and using multiple languages to identify all 
available evidence. Most importantly, the review included 
only qRT- PCR- confirmed ZIKV coinfections, which is the 
most accurate way to diagnose acute coinfections (ie, 
due to the very short time window of qRT- PCR testing 
(<7 days)) and limits misdiagnosis, which is of partic-
ular importance with the high cross- reactivity reported 
from arbovirus serology testing. On the other hand, by 
focusing on concurrent infections, the current review was 
unable to appraise the potential impact of recent infec-
tions; for example, it has been previously reported that 
pre- existing immunity to DENV, which shares a common 
vector and circulates in most of the countries reporting 
ZIKV coinfection, may influence the clinical presentation 
of ZIKV infection.53 The additional limitations of this 
review mainly stem from the lack of available high- quality 
evidence on ZIKV coinfections. Notably, the majority 
of included studies were rated level 4 or 5 according to 
the OCEBM Levels of Evidence. Only seven studies were 
rated level 2 or above. Additionally, the reported ZIKV 
coinfection types may have been influenced by the under-
lying prevalence of coinfecting pathogens in the popula-
tion and the applied diagnostic practices (ie, multiplex 
testing vs testing on clinician's suspicion). The use of 
specific case definitions in included cross- sectional and 
case series studies (eg, fever and rash15) may have also 
introduced a selection bias that potentially led to an over- 
representation of specific symptoms associated with ZIKV 
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coinfection reported for a given study (eg, reporting 
100% of cases as presenting with fever and rash).15 
Finally, the studies selected for this systematic review 
only included symptomatic ZIKV- infected cases, which 
represent only approximately 40% of all ZIKV cases.2 It 
is likely that the actual frequency of ZIKV coinfections 
may be higher as many cases will be asymptomatic and 
therefore never seek medical attention. However, the 
recently implemented multiplex PCR assay, which tests 
for CHIKV, DENV and ZIKV simultaneously, will likely 
improve the detection of ZIKV/arbovirus coinfections 
and facilitate future assessment of the frequency of ZIKV 
coinfections.54
In conclusion, the findings of this review suggest that 
the cocirculating arboviruses, CHIKV and DENV, are 
the most common ZIKV coinfection types and may, in 
specific populations and epidemiological contexts, occur 
in up to half of ZIKV infections. The evidence collated 
in this systematic review suggests coinfections do not 
markedly alter the generally mild clinical presentation 
of uncomplicated ZIKV disease. However, additional and 
better quality evidence should be prioritised in future 
outbreaks to corroborate the estimates of the frequency 
of ZIKV coinfections and to interrogate the importance 
of ZIKV coinfections in the development of ZIKV- related 
complications, especially for ZIKV coinfections with 
CHIKV and DENV.
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